Free Trial

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Update

BioMarin Pharmaceutical logo with Medical background

Key Points

  • BioMarin Pharmaceutical experienced a notable 20.2% increase in short interest in August, reaching 5,960,000 shares by the end of the month.
  • Several analysts have given conflicting ratings, with HC Wainwright assigning a "neutral" rating while UBS raised the price target to $114.00 and maintains a "buy" rating.
  • Hedge funds have increased their positions in BioMarin, with Goldman Sachs Group raising its holdings by 212.7% in the first quarter.
  • Five stocks to consider instead of BioMarin Pharmaceutical.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 5,960,000 shares, an increase of 20.2% from the August 15th total of 4,960,000 shares. Currently, 3.1% of the company's stock are short sold. Based on an average trading volume of 2,110,000 shares, the short-interest ratio is presently 2.8 days. Based on an average trading volume of 2,110,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.1% of the company's stock are short sold.

Analyst Upgrades and Downgrades

BMRN has been the subject of several recent analyst reports. Zacks Research downgraded shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. UBS Group lifted their price objective on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Wedbush reiterated an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. Guggenheim lifted their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th. Finally, Raymond James Financial started coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $85.00 price objective for the company. Fourteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $92.60.

Get Our Latest Stock Report on BMRN

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock traded down $0.42 during trading on Monday, hitting $53.94. 1,866,590 shares of the company's stock were exchanged, compared to its average volume of 1,901,207. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56. The business has a 50-day simple moving average of $57.51 and a 200-day simple moving average of $59.66. BioMarin Pharmaceutical has a 52-week low of $52.93 and a 52-week high of $73.51. The stock has a market capitalization of $10.36 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 0.69 and a beta of 0.35.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Dodge & Cox raised its holdings in shares of BioMarin Pharmaceutical by 1.0% during the second quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company's stock worth $830,504,000 after purchasing an additional 153,070 shares during the last quarter. Viking Global Investors LP raised its holdings in shares of BioMarin Pharmaceutical by 13.8% during the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company's stock worth $675,505,000 after purchasing an additional 1,488,552 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 90.7% during the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company's stock worth $306,429,000 after purchasing an additional 2,654,768 shares during the last quarter. Geode Capital Management LLC increased its holdings in BioMarin Pharmaceutical by 1.3% in the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company's stock valued at $190,417,000 after buying an additional 43,185 shares in the last quarter. Finally, Nuveen LLC purchased a new position in BioMarin Pharmaceutical in the first quarter valued at $184,475,000. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading

Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?

Before you consider BioMarin Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.

While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.